Welcome to our dedicated page for Catalyst Pharmaceuticals SEC filings (Ticker: CPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Catalyst Pharmaceuticals files regulatory disclosures that document material events for its rare-disease biopharmaceutical business and Nasdaq-listed common stock. Recent Form 8-K and 8-K/A filings cover operating results and business updates, Regulation FD presentation materials, press-release exhibits, and capital-structure matters including a board-authorized share repurchase program.
The filings also record company-specific legal and intellectual property disclosures, including FIRDAPSE Orange Book patent litigation, amendments to prior material-event reports, and settlement-related corrections. These documents tie formal disclosures to Catalyst’s commercial products, governance actions, exhibit filings, and public-company reporting obligations.
Catalyst Pharmaceuticals filed an amended current report to correct a naming error in an earlier update about a patent litigation settlement related to its FIRDAPSE® patents. The company had reported a prior settlement with “Inventia Life Science Pty Ltd,” but clarified that the correct party is Inventia Healthcare Limited.
The amendment states that no other terms of the previously disclosed settlement with Lupin or the related press release were changed. Catalyst attached the corrected August 26, 2025 press release as an exhibit, confirming that the update is purely to fix the identity of the earlier settling party.
Catalyst Pharmaceuticals filed an amended current report to correct a naming error in an earlier update about a patent litigation settlement related to its FIRDAPSE® patents. The company had reported a prior settlement with “Inventia Life Science Pty Ltd,” but clarified that the correct party is Inventia Healthcare Limited.
The amendment states that no other terms of the previously disclosed settlement with Lupin or the related press release were changed. Catalyst attached the corrected August 26, 2025 press release as an exhibit, confirming that the update is purely to fix the identity of the earlier settling party.
Catalyst Pharmaceuticals filed a Form 144 notice indicating a proposed sale of 26,000 common shares through Fidelity Brokerage Services LLC with an aggregate market value of $525,087.81. The filing lists the approximate date of sale as 08/27/2025 and names NASDAQ as the securities exchange. It records the number of shares outstanding as 122,391,010. The securities are reported as acquired by an option granted 12/19/2018 with an acquisition date shown as 08/27/2025, and the consideration on sale noted as cash. Several issuer and filer identification fields in the provided content are blank or not shown in the excerpt.
Catalyst Pharmaceuticals (CPRX) Form 144 shows a proposed sale of 115,000 common shares through Fidelity Brokerage Services with an approximate aggregate market value of $2,332,370.02. The filing lists the shares as acquired on 08/26/2025 upon exercise of an option originally granted on 12/19/2018, with the approximate date of sale also listed as 08/26/2025 on the NASDAQ.
The filer certifies no undisclosed material adverse information. No securities were reported sold by the person in the past three months. The notice indicates cash payment for the exercised option and identifies the broker and share count but does not provide the seller's name, percent ownership, or relationship to the issuer.
Catalyst Pharmaceuticals (CPRX) filing a Form 144 notifies the proposed sale of 22,970 common shares by a person for whose account the securities are to be sold, with an aggregate market value of $473,641.40. The shares are held at Fidelity Brokerage Services and the approximate sale date is 08/26/2025 on NASDAQ. The filing shows the shares were acquired on 08/26/2025 pursuant to an option granted on 12/19/2018, and the planned consideration is cash. The filer also reported a prior sale of 70,000 shares on 05/30/2025 generating gross proceeds of $1,740,171.80. The filer attests no undisclosed material adverse information.
Catalyst Pharmaceuticals, Inc. has entered into a settlement agreement with Lupin Ltd. and Lupin Pharmaceuticals, Inc. over patent litigation related to a proposed generic version of FIRDAPSE (amifampridine) 10 mg tablets. Under the agreement, Lupin will not market its generic FIRDAPSE in the United States any earlier than February 25, 2035, if it receives U.S. Food and Drug Administration approval, except in certain limited customary circumstances. All ongoing FIRDAPSE patent litigation between Catalyst, its licensor SERB S.A., and Lupin in the U.S. District Court for the District of New Jersey will be terminated. Catalyst notes that separate FIRDAPSE patent litigation against Hetero covering all Orange Book-listed patents remains ongoing, and there is no assurance that a generic version will be kept off the U.S. market until February 25, 2035.
Daniel J. Curran, a director of Catalyst Pharmaceuticals (CPRX), reports no direct common stock ownership and holds options to acquire 40,000 shares at an exercise price of $21.12. The options vest in three annual tranches beginning August 1, 2026 and expire on August 1, 2032, creating multi-year equity alignment with the company.
Period: Quarterly report for Catalyst Pharmaceuticals, Inc. (CPRX) for the six months ended June 30, 2025.
Key financials: Total revenues $287,984 thousand; product revenue $287,940 thousand; operating income $129,665 thousand; net income $108,845 thousand; diluted EPS $0.86; cash and cash equivalents $652,800 thousand; total assets $971,915 thousand as of June 30, 2025.
Product mix and material items: FIRDAPSE $168,576 thousand, FYCOMPA $69,959 thousand, AGAMREE $49,405 thousand for the six months ended June 30, 2025. Customer A accounted for 75.3% of net product revenue for the six months ended June 30, 2025. Company states it has sufficient funds for at least 12 months and completed a public offering on January 9, 2024 raising net proceeds of approximately $140.7 million.
Period: Quarterly report for Catalyst Pharmaceuticals, Inc. (CPRX) for the six months ended June 30, 2025.
Key financials: Total revenues $287,984 thousand; product revenue $287,940 thousand; operating income $129,665 thousand; net income $108,845 thousand; diluted EPS $0.86; cash and cash equivalents $652,800 thousand; total assets $971,915 thousand as of June 30, 2025.
Product mix and material items: FIRDAPSE $168,576 thousand, FYCOMPA $69,959 thousand, AGAMREE $49,405 thousand for the six months ended June 30, 2025. Customer A accounted for 75.3% of net product revenue for the six months ended June 30, 2025. Company states it has sufficient funds for at least 12 months and completed a public offering on January 9, 2024 raising net proceeds of approximately $140.7 million.